Investigator's Brochure
For anyone preparing or reviewing an IB: what a well constructed, fully compliant brochure needs to contain.
Download the free guideClinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipInsider’s Insights / Clinical Trial Registries
A practical guide to registering trials, reporting results and keeping your records consistent across every registry your programme touches.
Six things you will be able to do after reading this guide.
Register within 21 days of the first participant and report results within 12 months of primary completion under FDAAA 801.
How the FDA, EU CTR and CTIS, HRA/MHRA and WHO frameworks differ, and how to stay consistent across all of them.
Why registration is not a one-off task, from protocol development and amendments to long-term record maintenance.
The six discrepancies regulators and auditors look for, from outcome switching to unreported terminated studies.
What effective plain-language summaries require, and how patient representatives can strengthen them.
How journal editors and reviewers compare registered endpoints with what you publish, and how to keep them matched.
Three quick questions taken from the guide. Test what you already know.
0of 3 correct so far
Question 1 of 3
Under FDAAA 801, how long do you have to register a trial after the first participant is enrolled?
Question 2 of 3
How are UK trials of investigational medicinal products approved by the HRA/MHRA registered?
Question 3 of 3
Roughly how many clinical trials remain unpublished 2 to 5 years after completion?
The guide goes into each of these in depth, alongside the rest of what sponsors need to know about registry compliance.
Download the free guideA few of the 26 pages, so you know exactly what you are getting.
“A pragmatic future involves AI-supported transparency governance where technology enhances operational efficiency.”Justin Cook, Head of Medical Writing, from the interview in this guide
A clinical trial registry is a public database where trials are recorded to address publication bias and selective reporting. Regulators, journals, ethics committees, funders and patients now expect registry information to be accurate, complete and consistent throughout a study's lifecycle.
Requirements vary by jurisdiction and include FDAAA 801 in the US, the EU Clinical Trials Regulation via CTIS, WHO ICTRP, and HRA/MHRA rules in the UK. Most frameworks mandate registration shortly after first participant enrolment and results reporting within a set timeframe after primary completion.
Non-compliance is common because organisations often treat registry management as an isolated administrative task rather than an integrated operational discipline. Compliance rates differ significantly between large commercial sponsors and academic or non-industry sponsors, largely due to fragmented governance and limited resources.
CTIS operates on a principle of transparency by default, meaning documents submitted during regulatory review may become publicly accessible unless a deferral or redaction applies. This means sponsors must consider public disclosure implications from the earliest stages of protocol drafting.
AI can support repetitive tasks such as deadline monitoring and discrepancy detection, but experienced human oversight remains essential for judgement calls around commercial confidentiality, publication timing and cross jurisdictional obligations. Registry governance still requires scientific and regulatory expertise that technology cannot fully replace.
Registry entries, results summaries and lay summaries prepared to agency standards.